Trending...
- California: Governor Newsom announces appointments 3.20.2026
- California announces 300 wildfire projects fast-tracked in 300 days
- California: Governor Newsom proclaims Nowruz
PALO ALTO, Calif., May 20, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that management will present at the following upcoming virtual investor conferences:
A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com.
More on The Californer
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
SOURCE Kodiak Sciences Inc.
Related Links
http://www.kodiak.com
- Jefferies Virtual Healthcare Conference on Thursday, June 3 at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time)
- Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8 at 1:40 p.m. Pacific Time (4:40 p.m. Eastern Time)
A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com.
More on The Californer
- eBook Publishing Services in USA California Book Publishers Helps Authors Turn Ideas into Successful
- City of Long Beach to Host Recycle Your Bicycle Event on May 2
- Public Employees Are Asking: Are Our Pensions Secure?
- Understanding Unexpected Death: Why Independent Autopsies Matter in Cases Without Clear Cause
- Epic Pictures Group Sets North American Release Date for the Thriller NO ORDINARY HEIST
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
SOURCE Kodiak Sciences Inc.
Related Links
http://www.kodiak.com
Filed Under: Business
0 Comments
Latest on The Californer
- California: Governor Newsom announces CHP crackdown: 12,600 arrests, 6,400 stolen cars recovered, 25 million deadly fentanyl doses seized in two years
- Award-Winning REALTOR® Paige Coker Joins Corcoran DeRonja Real Estate
- License Plate Owner Lookup API Goes Live on RapidAPI and Postman Public Network
- Over 98% of crypto owners globally don't declare taxes, new report find
- TicTac Group acquires French EdTech company Distrisoft
- TL Foundation Supports Connect's 2026 Cool Companies to Strengthen San Diego's Innovation Economy
- Equestrian Expert Rominger Receives National Recognition Through the INDEPENDENT PRESS AWARD®!
- Scientology Network Celebrates International Day of Happiness with Global Marathon
- New Platform Helps Gig Workers Avoid Paying Taxes on Income They Never Received
- Comedian Marc Yaffee Headlines Willits High School Sober Grad Fundraiser Show
- California: Governor Newsom convenes leaders to confront crisis facing boys and men
- Governor Newsom launches campaign to recruit young men, and all Californians, to serve communities and gain job skills
- VCCCD Announces Ventura College Presidential Finalists
- Squeegex Expands Window Cleaning and Exterior Services Across 30+ San Diego Neighborhoods
- Long Beach: City Recognizes Tsunami Preparedness Week 2026: Know the Risk. Know the Route.
- Mark Dobosz Makes Donorassess.org Free To Every Nonprofit On The Planet
- THE DASH CAM: THINKWARE Launches Big Spring Sale on Select Dash Cam Models
- Genpak Announces Closure of Utah Manufacturing Facility
- Magai V3 Launches to Deliver a Faster, Cleaner, More Capable AI Workspace
- Newborn Care Network Introduces Clinical Standard to Bridge the Six-Week Postpartum Gap